Items of Interest
GDNF - An Alternate Method
of Delivery, by Parkinson's Med
Parkinson's Patients Plea to
Amgen: Third Anniversary,
by Parkinson's Med (a blog)
the Parkinson's Pipeline by Robin
Elliott, Executive Director of the Parkinsonís Disease Foundation
Terminated PD Experimental
Treatments 2004 - present / PD Drugs approved by FDA 2004 - present
Is there an
important pattern in the seemingly uninterrupted failure of drugs and biologics?
On the Toxicity of GDNF:
A challenge to Amgen's monkey GDNF
Compassion, Care, and Ethics for Seriously Ill Patients Act"
or the Access Act (S3046 ) was introduced in the Senate in May. It is
a bill to amend the Federal Food, Drug, and Cosmetic Act to create a new
conditional approval system for drugs, biological products, and devices
that is responsive to the needs of seriously ill patients, and for other
Library of Congress, Thomas
Clinical Research Rights and
Responsibilities for People with Parkinson's
Clinical research is
essential to the development of new
therapies and treatments for Parkinsonís disease. Yet, due to a number of factors,
including a lack of awareness and
understanding of the research
one percent of people with Parkinsonís
participate. This is far below the number
needed, delaying many promising trials.
"Ethical Issues in Clinical Neuroscience Research: A Patient's Perspective"
by Parkinson Pipeline Project members. Published in
Neurotherapeutic, Vol. 4, No. 3, 2007.
Read the article
Read the Testimony of Amy Comstock Rick, CEO-
Parkinsonís Action Network
For the U.S. House of Representatives Committee on Small Business
Subcommittee on Investigations and
Oversight. Hearing on "SBIR: Advancing
University of Rochester to study ethics of sham surgery [no
longer on line]
READ Andy Grove's speech to the Society for
Neuroscience in its entirety
to view selected video clips from Andy Grove's speech at the Society for
November 4, 2007
Profit Over Common Sense
Updated GDNF Information
in Parkinsonís clinical research.
The Results of
the recent poll.
Answers About "Off-Label" Use of Prescription Drugs
The Prescription Drug User Fee Act
of 2007 (PDUFA)
Parkinson's patients for genetic study (5/24/07)
The NIH is seeking
Parkinsonís patients to participate in their study of
ďPhenotype/Genotype Correlations in Movement Disorders.Ē Itís purpose is
to identify possible genetic causes of movement disorders, including PD.
A description of the study is available on Clinicaltrials.gov web site
One of the Pipeline members who volunteered for this study stated it
involves a 2 day visit to the NIH (which was very interesting in
itself), a complete physical exam and drawing of blood samples.
From the NIH:
Researchers at the National Institutes of Health are seeking Parkinsonís
disease subjects who are between 21-90 years of age and otherwise good
health to participate in various research studies.
We invite you to take part in an investigational research study Genetic
Characterization of Movement Disorders. We are seeking subjects and
family members who have been diagnosed with Parkinsonís disease.
If you have Parkinsonís disease and would like to consider taking part
in important research studies at the NIH, there is no cost to
participate. Participants will return to their own physicianís care
after taking part in a study.
NIH will provided travel and hotel, if needed.
For more information, Please call
Mae Brooks at 301-496-4604 or
This study is conducted under safety and testing standards of the
Department of Health and Human Services.
Raising Trust in Parkinsonís Clinical Trials,
Marshall Loeb reports
on an innovative roundtable on Building Patient
Trust: A New Era of Clinical Research Rights and Responsibilities